Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis

Bridda A, Padoan I, Mencarelli R, et al.: Peritoneal mesothelioma: a review. MedGenMed 2007;9:32

Becklake MR, Bagatin E, Neder JA: Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int J Tuberc Lung Dis. 2007;11:356–369

Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet. 2005;366:397–408. doi: 10.1016/S0140-6736(05)67025-0

Grondin SC, Sugarbaker DJ. Malignant mesothelioma of the pleural space. Oncology (Williston Park). 1999;13:919–926 .

Ismail-Khan R, Robinson LA, Williams CC Jr, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13:255–263 .

Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2–17. doi: 10.1053/sonc.2002.30227

Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004;159:107–112. doi: 10.1093/aje/kwh025

Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603. doi: 10.1056/NEJMra050152

Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007; 45:379–387. doi: 10.2486/indhealth.45.379

Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer 2004;5(Suppl 2):S46–S50

Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7:147–154. doi: 10.1038/nrc2068

Luo S, Liu X, Mu S, et al. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China. I. Review of exposure and epidemiological data. Occup Environ Med. 2003;60:35–41. doi: 10.1136/oem.60.1.35

Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000; 44:565–601 .

Suzuki Y, Yuen SR, Ashley R. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ Health. 2005;208:201–210. doi: 10.1016/j.ijheh.2005.01.015

Yarborough CM. Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol. 2006;36:165–187. doi: 10.1080/10408440500534248

Bernstein DM, Chevalier J, Smith P. Comparison of Calidria chrysotile asbestos to pure tremolite: final results of the inhalation biopersistence and histopathology examination following short-term exposure. Inhal Toxicol. 2005;17:427–449. doi: 10.1080/08958370591002012

Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther. 2002;1:348–353 .

Bocchetta M, Di Resta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A. 2000;97:10214–10219. doi: 10.1073/pnas.170207097

Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006;103:10397–10402. doi: 10.1073/pnas.0604008103

Choe N, Tanaka S, Xia W, et al. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 1997; 105(5):1257–1260. doi: 10.2307/3433543

Xu A, Zhou H, Yu DZ, et al. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect. 2002;110:1003–1008 .

Shukla A, Gulumian M, Hei TK, et al. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med. 2003;34:1117–1129. doi: 10.1016/S0891-5849(03)00060-1

Liu Z, Klominek J. Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors. Anticancer Res. 2004; 24:1625–1630 .

Galffy G, Mohammed KA, Dowling PA, et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 1999;59:367–371 .

Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–475. doi: 10.1002/path.824

Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A. 2001;98:12032–12037. doi: 10.1073/pnas.211026798

Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 2002; 62:6065–6069 .

Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J. Cell. Physiol. 1999; 180: 150–157. doi: 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H

Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005; 65: 8090–8095. doi: 10.1158/0008-5472.CAN-05-2312

Testa JR, Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin. Cancer Biol. 2001; 11:31–38. doi: 10.1006/scbi.2000.0344

Xiao GH, Gallagher R, Shetler J, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol. 2005; 25: 2384–2394. doi: 10.1128/MCB.25.6.2384-2394.2005

Xiao GH, Beeser A, Chernoff J, Testa JR: p21-activated kinase links Rac/Cdc42 signaling to merlin. J. Biol. Chem. 2002;277: 883–886. doi: 10.1074/jbc.C100553200

Poulikakos PI, Xiao GH, Gallagher R, et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006; 25: 5960–5968. doi: 10.1038/sj.onc.1209587

Carbone M, Pass HI, Miele L, et al. New developments about the association of SV40 with human mesothelioma. Oncogene. 2003; 22:5173–5180. doi: 10.1038/sj.onc.1206552

Pass HI, Bocchetta M, Carbone M. Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin. 2004;14:489–495 .

Cutrone R, Lednicky J, Dunn G, et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 2005;6:10273–10279. doi: 10.1158/0008-5472.CAN-05-2028

Wong M, Pagano JS, Schiller JT, et al. New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst. 2002;94(24):1832–1836 .

López-Ríos F, Illei PB, Rusch V, et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004;364:1157–1166. doi: 10.1016/S0140-6736(04)17102-X

Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat Rev Cancer. 2002; 2:957-964. doi: 10.1038/nrc947

Shivapurkar N, Wiethege T, Wistuba II, et al. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem. 1999;76:181–188. doi: 10.1002/(SICI)1097-4644(20000201)76:2<181::AID-JCB2>3.0.CO;2-9

Carbone M, Rizzo P, Pass H. Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res. 2000;20:875–877 .

Bocchetta M, Eliasz S, De Marco MA, et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008; 68:1022–1029. doi: 10.1158/0008-5472.CAN-07-5203

Foddis R, De Rienzo A, Broccoli D, et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene. 2002;21:1434–1442. doi: 10.1038/sj.onc.1205203

Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene. 2003; 22: 81–89. doi: 10.1038/sj.onc.1206097

Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A. 2006;103:14128–14133. doi: 10.1073/pnas.0604544103

Robinson C, van Bruggen I, Segal A, et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006;66:10786–10794. doi: 10.1158/0008-5472.CAN-05-4668

Pietruska JR, Kane AB. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res. 2007;67:3637–3645. doi: 10.1158/0008-5472.CAN-05-3727

Saffiotti U: mesothelioma carcinogenesis:in vivo models. In: Pass HI, Vogelzang NJ, Carbone M (eds), malignant Mesothelioma. New York NY, Springer, 2005, pp 60.

Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol. 2001;27:214–215. doi: 10.1053/ejso.2000.1024

Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354–1365 .

Brown LM, Howard RA, Travis LB. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:2741–2742. doi: 10.1002/cncr.22309

Teta MJ, Lau E, Sceurman BK, et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109:1432–1438. doi: 10.1002/cncr.22526

Cavazza A, Travis LB, Travis WD et al. Post-irradiation malignant mesothelioma. Cancer. 1996;77:1379–1385. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.0.CO;2-Y

Andersson M, Wallin H, Jönsson M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer. 1995;63:330–336. doi: 10.1002/ijc.2910630304

Comin CE, de Klerk NH, Henderson DW. Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis? Ultrastruct Pathol. 1997;21:315–320. doi: 10.3109/01913129709021929

Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol. 2008;4:341–349. doi: 10.2217/14796694.4.3.341

Kaufman AJ, Pass HI. Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2008;8:293–303. doi: 10.1586/14737140.8.2.293